A Study of Initial Therapy for Glaucoma in Southern India: India Glaucoma Outcomes and Treatment (INGOT) Study

Abstract

Purpose: To compare initial glaucoma therapy with medications and trabeculectomy in southern India.

Methods: Patients aged ≥30 years newly diagnosed with glaucoma were randomized to trabeculectomy with 5-fluorouracil or medical therapy. Subjects with best-corrected vision <6/18 due to cataract underwent phacoemulsification (phaco/intraocular lens, IOL). Intraocular pressure (IOP), vision and visual function were assessed at 12 months.

Results: Patients assigned to medications and surgery received the expected therapy in 86% (172/199) and 64% (126/199) of cases, respectively. Forty patients (20%) assigned to surgery refused any treatment and 33 (17%) received medications. Among 199 patients randomized to medications, 52 (26.1%) underwent phaco/IOL, as did 89/199 (43.7%) of patients randomized to trabeculectomy. Baseline parameters of the two groups did not differ, nor did 1-year follow-up rates (medication 65%, trabeculectomy 58%, P = 0.15). Final IOP was lower with randomization to trabeculectomy (16.3 ± 5.1 mmHg) than medication (18.8 ± 6.7 mmHg, P < 0.0001). In regression models, randomization to trabeculectomy (P < 0.0001) was associated with lower IOP, and simultaneous trabeculectomy and cataract surgery was associated with higher IOP (P = 0.008) than trabeculectomy alone. Subjects receiving Phaco/IOL had significantly better final acuity (P < 0.0001) and visual function (P = 0.035), despite concurrent glaucoma treatment. Final visual acuity was worse in those receiving trabeculectomy in addition to cataract surgery, but this was of borderline significance (P = 0.06).

Conclusions: Trabeculectomy lowered IOP significantly more than medical treatment, but with slightly greater loss of visual acuity. Combined phaco/IOL and trabeculectomy improved visual acuity with substantial IOP lowering.

Keywords::

• India
• Glaucoma
• Cataract
• Trabeculectomy
• Medication
• Therapy

ACKNOWLEDGMENTS

Financial Support: Funding for this study was provided by Pfizer, Inc., and donors to the Wilmer Glaucoma Research Fund; eyedrop medications were provided by Pfizer, Inc., Allergan, Inc., and Merck, Inc., and intra-ocular lenses were provided by Alcon Laboratories.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.